Skip to main content

Table 2 Clinical and laboratory features at MAHA diagnosis and association with 4-week survival

From: Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study

   Univariate analysis   Multivariate analysis  
Factors N (%) OR 95% IC p value OR 95% IC p value
PS at MAHA diagnosis
 PS 1–2 30 (55.6%) 1.0   0.003 1.0   0.01
 PS 3–4 24 (44.4%) 6.0 [1.8; 19.8]   7.0 [1.6; 31.8]  
Clinical bleeding
 Yes 9 (16.7%) NS    NS   
 No 45 (83.3%)       
Neurological symptoms
 Yes 15 (28.3%) NS    NS   
 No 38 (71.7%)       
 NA 1       
Dyspnoea
 Yes 11 (20.8%) NS    NS   
 No 42 (79.2%)       
 NA 1       
Metastatic sites
 < 3 25 (46.3%) NS    NS   
 ≥ 3 29 (53.7%)       
Metastasis
 Bone marrowa 11 (78.5%)       
 Bone 44 (81.5%)       
 Lung 8 (14.8%) NS    NS   
 Liver 35 (64.8%)       
 Otherb 24 (44.4%)       
Number of prior treatment lines
 ≤ 1 26 (48.1%) 1.0   0.06 NS   
 > 1 28 (51.9%) 2.9 [1.0; 8.7]     
Platelets
 < 50 G/L 29 (53.7%) NS    NS   
 ≥ 50 G/L 25 (46.3%)       
Haemoglobin
 < 8 g/L 26 (48.1%) 4.0 [1.3; 12.5] 0.02 3.7 [0.9; 16.7] 0.08
 ≥ 8 g/L 28 (51.9%) 1.0    1.0   
Schistocytes
 > 5.0% 10 (25.0%) NS    NS   
 0.5–5.0% 30 (75.0%)       
 NA 14       
Erythroblastemia
 Yes 40 (85.1%) NS    NS   
 No 7 (14.9%)       
 NA 7       
Myelemia
 Yes 38 (90.5%) NS    NS   
 No 4 (9.5%)       
 NA 12       
Prothrombin time
 < 50% 8 (16.0%) 4.5 [0.9; 25.0] 0.07 9.1 [1.2; 50.0] 0.03
 ≥ 50% 42 (84.0%) 1.0    1.0   
 NA 4       
Fibrinogen
 ≤ 2 g/L 15 (34.9) NS    NS   
 > 2 g/L 28 (65.1)       
 NA 11       
Glomerular filtration eate
 > 60 mL/min 25 (65.8%) NS    NS   
 30–60 mL/min 9 (23.7%) NS      
 < 30 mL/min 4 (10.5%) NS      
 NA 16       
Total bilirubin level
 < 1.24 mg/dL 16 (30.8%) 1.0   0.007 1.0   
 ≥ 1.24 mg/dL 36 (69.2%) 7.3 [1.8; 30.6]   6.9 [1.1; 42.6] 0.04
 NA 2       
Pronopall scorec
 Short survival 12 (31.6%) 3.7 [0.8; 16.8] 0.09    
 Intermediate/long survival 26 (68.4%) 1.0    NS   
 NA 16       
  1. NA not available, OR odds ratio, NS non-significant
  2. aOnly 14 patients had a bone marrow examination (myelogram or bone marrow biopsy) at the time of BC-MAHA diagnosis
  3. bOthers metastatic sites: cerebral, carcinomatous meningitis, node involvement
  4. cThe pronopall score for early death among oncology patients was calculated according to Barbot et al., J Clin Oncol 2008, missing data being imputed